BioMark Receives European Patent for Cancer Diagnostic

Vancouver, British Columbia – (June 18, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that the company has been granted a patent titled “A METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRANSFERASE.”  The method comprises correlating a presence of the acetylated metabolite of rimantadine or tocainide to spermidine/spermine N1-acetyltransferase activity.  The patent will cover a novel approach to diagnosing and monitoring various forms of cancer.

 

Cancer is one of the leading causes of deaths in the world and prevalence of the disease has been increasing.  The global cancer diagnostics market size was valued at $144. 4 billion in 2018 and is expected to register a CAGR of 7.0% over the forecast period. Rising awareness and supportive government initiatives are some additional factors anticipated to boost market growth during the forecast period.

 

“Receiving this critical patent reaffirms our commitment to enhancing and developing our core cancer technology platform,” said Rashid Bux, Chief Executive Officer of BioMark Diagnostics Inc. “This patent bolsters our intellectual property beyond a single compound, providing us the ability to select potentially better signaling candidates which can be targeted for specific or more fatal cancers.  We have expanded our portfolio of solid candidates that supports our unique and non-invasive approach of using in many cases, a selective single dose FDA off label drugs as “smart probes” for diagnostic applications.  Our approach offers clinicians and patients an additional set of tools to help better manage the cancer continuum of care.”

Press Release – BioMark Receives European Patent for Cancer Diagnostic

BIO STREAM DIAGNOSTICS INC. SELECTED FOR CDL RAPID RESPONSE INNOVATION PROGRAM

Vancouver, British Columbia – (June 16, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that its affiliated company, Bio Stream Diagnostics Inc., was selected to participate in the global academic science and tech startup program Creative Destruction Lab’s (CDL) recent dedicated Recovery program. CDL Recovery is designed to help turn science and research work into scalable products and services to address the consequences of the COVID-19 pandemic, in terms of both its effects on public health and the economy. CDL Recovery is focused on the full stack of information-based solutions in an attempt to accelerate the world’s recovery from the COVID-19 crisis.

 

CDL Recovery focuses on information-based solutions. These include, for example, managerial decision-making tools based on: (1) swab-based tests that predict whether the coronavirus is present in an individual, (2) contact tracing, (3) image analysis of people density or proximity, (4) symptom monitoring, and (5) workplace monitoring of air or sewage.

 

“We are extremely proud to have been selected for the prestigious and important science and tech-based initiative,” said Mr. Rashid Bux, CEO of BioMark Diagnostics.  “We look forward to the valuable guidance from CDL’s experts and established network as we begin to work towards bringing our rapid COVID-19 screening platform to market.”

 

The CDL Recovery program will follow the same structure as its standard streams but will be done at twice the pace in order to expedite the results. The program is available at no cost, and without any equity taken by any of the program operators. Effective objective setting is the cornerstone of the program. Meetings with CDL mentors have a purpose of assessing progress and setting new objectives. Companies that underperform on their objectives are periodically cut from the program.

 

About CDL

Creative Destruction Lab (CDL) is a non-profit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies.

CDL’s model for helping startups move from concept to product is fairly unique, and potentially well-suited to addressing new needs that emerge as a result of how the world is changing in response to the novel coronavirus. Many of the efforts to address needs both in terms of therapeutics and in medical hardware to help shore up shortages are originating at schools and universities around the world, and CDL’s expertise heavily favors moving deep tech and hard science from inside the research lab to the market.

 

The program is aimed at helping usher innovations from product in key areas, including around diagnostic testing, vaccine development, remote care and telemedicine, as well as in areas of economic support like virtual work, talent re-training, remote equipment operation, automation and food production and supply. CDL founder and University of Toronto professor Ajay Agrawal said in a blog post about the new program that many have suggested there’s a need “to assume a wartime footing in response to COVID-19,” and that’s one of the aims of the program.

It’s definitely true that crises like the one we face currently have a way of decreasing the turnaround time from research to development and deployment. And already, CDL’s program is designed from the ground-up to try to accelerate the pace at which that happens, working with academic institutions around the world, including the University of Oxford, HEC Paris, the Georgia Institute of Technology,  the University of British Columbia, HEC Montreal, the University of Calgary  and Dalhousie University, as well as the University of Toronto. Teams that are approved to join take part in a series of sessions that set objectives, and then measure their progress, guided by mentors, including the founders and executives of world-leading companies and institutions.

 

CDL mentors include accomplished medical and health experts, entrepreneurs, experienced operators, active angel and venture investors, world-leading scientists, engineers, and economists. Mentors meet via the Virtual CDL platform to help founders set objectives over the duration of the program.  CDL Recovery is divided into Economic Recovery or Public Health. Mentors in both streams can be accessed via: https://www.creativedestructionlab.com/people/

 

About Bio Stream Diagnostics Inc.

Bio Stream Diagnostics Inc is developing a novel COVID-19-detection method leveraging new generation Raman spectroscopy and the power of machine learning an alternative detection tool to polymerase chain reaction (PCR) detection arrays and other detection systems.

 

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/.

Press Release – BioStream Diagnostics Inc. Selected for CDL Rapid Response Innovation Program

BioMark Diagnostics Inc. Clarifies Prior Disclosure

Vancouver, British Columbia – (June  11 , 2020) – – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a  developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and cost effectively, wishes to include additional information to clarify the disclosures in its news release disseminated by the Company on June 10, 2020 with respect to the formation of Bio Stream Diagnostics Inc., a new company, focused on providing low-cost COVID-19 detection in less-than-30 seconds. Leveraging Raman spectroscopy and the power of machine learning, the Bio Stream platform is anticipated to provide low-cost, accurate results in coronavirus screening. The clarification was requested by IIROC and offers expanded disclosure that is addressed below.

 

Equipment Sourcing, Set-Up, and Training Information

Bio Stream Diagnostics Inc. will not manufacture the testing units. The Raman system is manufactured by Ocean Insight a leading North American applied spectral knowledge company. The manufacturer will be bringing expertise in spectroscopy and custom system design, dedicated system design and engineering teams, and ISO 9001 manufacturing capabilities. The manufacturer will also supply specially designed nano probes (substrates) that can be used to amplify the signal and enhance detection of the virus. The size of the system will be similar to a desktop computer and will only require access to power and internet. The system is being designed for very minimal training. The equipment set up training will be conducted virtually by scientific officials from the manufacturing company. The estimated initial cost for a single testing unit along with a computer is Cdn. $40,000.

Product Development Status And Regulatory Plan

The general overview of the project will be to ship a certified Raman hardware and install the hardware in Dr. Bach’s  level 3 lab where it will be used to obtain Raman spectra of COVID-19 infected and uninfected samples. Dr. Bach is at the University of British Columbia has extensive expertise in recombinant antibody generation and is also working on a project related to the development of antibodies against SARS-CoV-2.  Data from these measurements will be used to create machine learning models, which will be compared to results from traditional PCR* in a side-by-side comparison, and then be integrated into the spectrometer system software.  More Raman hardware might be assembled and shipped to partnering labs and approved sites across the country to further test and validate the system if needed. It is estimated that will take about 16 weeks to test and prove the system.  The tests will be based on strict protocols that are being designed and reviewed by a team that includes regulatory experts, scientists, diagnostic experts, and a virologist. Subsequently if the system meets the desired viability standards, the team will assess methods to optimize the overall system and eventually develop a plan to scale the offering with the manufacturer.

Bio Stream Diagnostics Inc. will follow the requirements under Health Canada regulations that stipulates sample size and necessary comparisons. The team regularly consults the following  Health Canada website for guidance – https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/application-information/guidance-documents/covid19-requirements-serological-antibody-tests.html#a659

Disclaimer – Health Canada/FDA approvals would be required prior to any sell of any testing units

*Polymerase chain reaction (PCR) is a laboratory technique used to detect the presence or absence of certain genomic fragments (DNA).

Raw Material and Sample Sources
The raw materials needed to run the tests will be sourced from approved biological suppliers that Dr. Bach has used given his expertise in infectious disease. All the materials will be shipped to Dr. Bach’s facility. Biological samples from authorized bio banks will include nasopharyngeal swabs and potentially saliva.

The current costs incurred for the hardware and related supplies will be paid by Bio Stream Diagnostics Inc. The company (Bio Stream Diagnostics Inc.) has applied for various grants and has submitted proposals to several agencies in Canada and the USA. In addition, the company (Bio Stream Diagnostics Inc.) may seek additional capital to fund the venture based on the results of the test.

Press Release – BioMark Diagnostics Inc. Clarifies Prior Disclosure

BioMark Diagnostics Forms New Company, Bio Stream Diagnostics Inc., for ‘30-Second’ COVID-19 Screening

Rapid COVID-19 testing will use machine learning and advanced Raman spectroscopy to provide low-cost, accurate results

 

Vancouver, British Columbia – (June  10 , 2020) – – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a  developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and cost effectively, announced today that the Company has partnered with Stream.ML and Merogenomics to form Bio Stream Diagnostics Inc., a new company, focused on providing low-cost COVID-19 detection in less-than-30 seconds. Leveraging Raman spectroscopy and the power of machine learning, the Bio Stream platform will provide low-cost, accurate results in coronavirus screening.

 

“Management is extremely pleased to announce this critical endeavor with such renowned leaders in their respective fields,” said Rashid Bux, Chief Executive Officer of BioMark Diagnostics Inc.  “We believe that rapid and cost-effective testing is a vital step in combating the COVID-19 pandemic, and our goal is to introduce this rapid-screening platform to the global market in the coming weeks.  We are currently engaged in high-level discussions with governmental agencies regarding a potential rollout strategy.”

 

This project brings together domain experts in multiple disciplines through Stream.ML and BioMark, including scientists, virologists, equipment manufacturers, and academic and health institutions. Stream.ML was established in 2012 as a machine learning company with expertise in optics, spectral data, spectroscopy, and deep learning.  Merogenomics Inc., based in Edmonton, Canada, was founded by Dr. Mikolaj Raszek in 2015, and was conceived to make the benefits of genome sequencing accessible to the general public.

 

New Testing Platform Benefits Include:

 

  • Low-cost (including both consumables and analytics)
  • Rapid detection (machine learning models will return instant results) < 30 s per test
  • Simplified sample handling processing for use in any health facility
  • Ability to be run by non-technical lab personnel
  • High sensitivity and specificity
  • Use of less consumables compared to PCR
  • Can be used as a screening tool or additional verification for other tests
  • Rapid and economical set up – can be set up in countries with limited infrastructure
  • Connectivity and wireless data transmission to a centralized health institution/monitoring system

 

Bio Stream’s COVID-19 screening is focused on fundamentally changing how testing will be done on a global basis. The objective of Bio Stream Diagnostics is to develop an alternative detection tool to polymerase chain reaction (PCR) detection arrays and other detection systems.  Surface-enhanced Raman spectroscopy (SERS) is uniquely suited to detect viruses and small molecules, and machine learning is well-suited for the analysis of this type of data. This will be a turnkey testing system, complete with a compact spectrometer, software, model execution, scanning instructions, and SERS substrates for disposable sample collection. Collectively, this team has the necessary experience of medical-based product delivery and machine learning distribution from a global commercialization perspective. Each company will be contributing distinct IPs and technical expertise in the venture. Officers from the 3 companies will be directors of the new company.

Press Release – BioMark Diagnostics Forms New Company